Current developments in prevention and treatment of candidiasis: A review

Prodipta Chakraborty; Darshan  Pradhan; Sudip Halder; Arnab Bagchi

doi:10.18231/j.joapr.2021.v9.i3.21-25

Authors

Prodipta Chakraborty Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim 737136
Darshan Pradhan Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim 737136
Sudip Halder Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, East Sikkim 737136
Arnab Bagchi Himalyan Pharmacy Institute, Department of Pharmaceutics, Rangpo, Sikkim

DOI:

https://doi.org/10.18231/j.joapr.2021.v9.i3.21-25

Keywords:

Candida, fungus, infection, oral, species, yeasts, patient, diagnosis, treatment, prevention

Abstract

Invasive fungus infection affects about six people out of every 100,000 people each year. Only half of these infections are detected throughout the patient's lifetime, making it one of the most common causes of death among intensive-care patients. The low detection rate is due to the diagnostic work's complexity, which comprises clinical, radiographic, and microbiological results. Antimycotic drug-resistant fungi are on the rise all over the world. Guidelines for identifying and treating invasive fungous infections caused by Candida spp., Aspergillus spp., Mucorales, and Fusarium spp. are the topic of this review. In typical hospital care, intrusive fungous infections are frequently ignored. They must include it as a necessary component of antimicrobial stewardship programmes. There is also a great need for novel antimycotic medication classes to be developed

Downloads

Download data is not yet available.

References

Quindos G, Alonso SG, Arias CM, Sevillano E, Mateo E, Jauregizar N, Eraso E. therapeutic tools for oral candidiasis: current and new antifungal drugs. Oral medicine and pathology, 24(2),172-180 (2019)

Garg A, Sharma GS, Goyal AK, Ghosh G, Rath G. recent advances in topical carriers of ant-fungal agent. Heliyon Ind.J.Pharm.Sci, 6, 1-12 (2020)

Janus MM, Willems HME, Krom BP. candida albicans in multispecies oral communities; a keystone commensal? Int.J.Pharm.Sci.Research, 6 (7),17-25 (2016)

Lei.J, Wang.T. Invitro susceptibility of candid spp to fluconazole, itraconazole and voriconazole and the correlation between triazole susceptibility: results from a five-year study. J.Medical.Health Sci, 28(9), 310-313 (2018)

Donder GG, Grincevicience S, Ruban K, Bellen G. Vaginal pH and microbota during fluconazole maintence treatment for recurrent vulvovaginal candidiasis(RVVC). Diagnostic microbiology and infectious disease Ind.J.Pharm.Sci, 7(5) 1-6 (2020)

Ruhnke M, Groll AH, Mayser P. Estimated burden of fungous infections in Germany. Mycoses, 58 ( 5), 22–8 (2015)

Bitar D, Lortholary O, Le SY. Population-based analysis of invasive fungous infections. France, 2001–2010. Emerg Infect Dis, 20, 1149–55 (2014)

Gauglitz G.G, Callenberg H, Weindl G, Korting HC. Host defense against C. albicans and the role of pattern-recognition

Lortholary O, Petrikkos G, Akova M. Guideline for the diagnosis and management of Candida disorders 2012: patients with HIV infection or AIDS. Clin. Microbiol. Infect, 18(7), 68–77 (2012)

Powderly WG, Finkelstein D, Feinberg J. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N. Engl. J Med, 332, 700–705 (1995)

Ruhnke M, Rickerts V, Cornely OA. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses, 54, 279–310 (2011)

Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE, Perfect JR. Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. Res. Hum. Retroviruses, 15, 1619–23 (1999)

Soysa NS, Samaranayake LP, Ellepola AN. Antimicrobials as a contributory factor in oral candidosis – a brief overview. Oral Dis, 14, 138–43 (2008)

Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol, 42, 698–702 (2006)

Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin. Infect. Dis, 33, 1959–67 (2001)

Ruhnke M, Rickerts V, Cornely O.A, Buchheidt D, Glockner A, Heinz W, Hohl R, Horre R, Karthaus M, Kujath P, Willinger B, Presterl E, Rath P, Ritter J, Glasmacher A, Lass-Florl C, Groll A.H. Diagnosis and therapy of Candida infections. Joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses, 54(4), 279-310 (2011)

Cassone A, Casadevall, A. Recent progress in vaccines against fungal diseases. Curr. Opin. Microbiol.,15(4), 427-33 (2012)

http://en.wikipedia.org/wiki/Vaccine.

Liu M, Clemons KV, Johansen ME, Martinez M, Chen V, Stevens D.A. Saccharomyces as a vaccine against systemic candidiasis. Immunol. Invest, 41(8), 847-55 (2012)

Garcia CC, Sarrion- PMG, Bagán JV. Current treatment of oral candidiasis: A literature review. J. Clin. Exp. Dent, 6, 576- 82 (2014)

Lyu X, Zhao C, Yan ZM, Hua H. Efficacy of nystatin for the treat¬ment of oral candidiasis: a systematic review and meta-analysis. Drug. Des. Devel. Ther, 10, 1161-1171 (2016)

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Os¬trosky-Zeichner L. Clinical practice guideline for the manage¬ment of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis, 62, 46-50 (2016)

Gotzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane. Database. Syst. Rev, 9, 233- 238 (2014)

Scheibler E, Garcia MCR, Medina DSR, Figueiredo MA, Salum FG, Cherubini K. Use of nystatin and chlorhexidine in oral medicine: Properties, indications and pitfalls with focus on geriatric patients. Gerodontology. 34, 291-8 (2017)

Lyu X, Zhao C, Yan ZM, Hua H. Efficacy of nystatin for the treat¬ment of oralcandidiasis: a systematic review and meta-

Kullberg BJ, Arendrup MC. Invasive Candidiasis. N. Eng. J Med, 373, 1445–56 (2015)